Abstract
The properties of heparin, a key anticoagulant, are reviewed. The important issues in heparinotherapy, i.e., reaching quick anticoagulant effect, maintaining therapeutic level of anticoagulation, heparin inhibition and non-invasive heparin formulations have been reviewed and discussed, with the focus on the role of polymeric substances in the proposed solutions.
Keywords: Heparin, anticoagulation, unfractionated heparin, low molecular weight heparin, heparin reversal, noninvasive delivery, heparinotherapy, heparin inhibition, polymeric substances, glycosaminoglycans (GAGs)
Current Pharmaceutical Design
Title:Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Volume: 18 Issue: 18
Author(s): Krzysztof Szczubialka, Kamil Kaminski, Katarzyna Zasada, Anna Karewicz and Maria Nowakowska
Affiliation:
Keywords: Heparin, anticoagulation, unfractionated heparin, low molecular weight heparin, heparin reversal, noninvasive delivery, heparinotherapy, heparin inhibition, polymeric substances, glycosaminoglycans (GAGs)
Abstract: The properties of heparin, a key anticoagulant, are reviewed. The important issues in heparinotherapy, i.e., reaching quick anticoagulant effect, maintaining therapeutic level of anticoagulation, heparin inhibition and non-invasive heparin formulations have been reviewed and discussed, with the focus on the role of polymeric substances in the proposed solutions.
Export Options
About this article
Cite this article as:
Szczubialka Krzysztof, Kaminski Kamil, Zasada Katarzyna, Karewicz Anna and Nowakowska Maria, Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers, Current Pharmaceutical Design 2012; 18 (18) . https://dx.doi.org/10.2174/138161212800492840
DOI https://dx.doi.org/10.2174/138161212800492840 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Ethanol Induced Oxidative Stress in the Vasculature: Friend or Foe
Current Hypertension Reviews Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology Microarray Applications in Occlusive Vascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Carotenoids on Health: Are All the Same? Results from Clinical Trials
Current Pharmaceutical Design Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Combination Therapy in Fibromyalgia
Current Pharmaceutical Design Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening The Role of AGEs in Cardiovascular Disease
Current Pharmaceutical Design Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease
Current Pharmaceutical Design Perioperative Management of Obese Parturients
Current Women`s Health Reviews Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry